Neuroleptic Malignant Syndrome: Pathophysiology, Diagnosis & Treatment

Added:

The Lethal Catatonia Spectrum Hypothesis

While traditional medical education treats Neuroleptic Malignant Syndrome (NMS) as a distinct, drug-induced emergency, an alternative perspective argues that NMS is actually a drug-induced variant of malignant catatonia. Proponents of the 'Lethal Catatonia Spectrum' hypothesis suggest that NMS, malignant catatonia, and serotonin syndrome share a common underlying pathophysiology involving severe dysregulation of the central dopamine, GABA, and serotonin systems. This view highlights the significant clinical and symptomatic overlap between these conditions, noting that they often respond to the same treatments, such as benzodiazepines and electroconvulsive therapy (ECT). Critics of the conventional, rigid categorization of NMS argue that treating it as an entirely isolated entity can lead to diagnostic confusion, misattribution of symptoms, and delayed treatment, especially when patients present with features of both catatonia and NMS.

Basic psychopharmacology, specifically the classification and mechanism of action of first-generation (typical) and second-generation (atypical) antipsychotics.
Dopaminergic pathways in the central nervous system, particularly the role of D2 receptors in the basal ganglia and hypothalamus.
The physiology of thermoregulation and autonomic nervous system control over heart rate, blood pressure, and sweating.
Skeletal muscle physiology, including the mechanisms of muscle contraction and the clinical significance of creatine kinase (CK) release.
Differential diagnosis of acute drug-induced hyperthermic syndromes, specifically distinguishing NMS from Serotonin Syndrome, Malignant Hyperthermia, and Anticholinergic Toxicity.
Advanced pharmacology of NMS rescue agents, including the mechanisms of Dantrolene (ryanodine receptor antagonist) and Bromocriptine (dopamine agonist).
Clinical protocols for safely reintroducing antipsychotic medications to a patient with a documented history of NMS.
Emergency management of severe rhabdomyolysis and acute kidney injury (AKI) secondary to severe muscle rigidity.
100.3K views1.5Klikes8:13@RhesusMedicineOriginal Release: 2022-08-29

Neuroleptic Malignant Syndrome is a life-threatening reaction to dopamine receptor antagonist medications (primarily antipsychotics), characterized by the FEVER mnemonic: Fever (typically >38°C), Encephalopathy (mental status changes), Vital sign instability (tachycardia, labile BP), Elevated enzymes (CK from rhabdomyolysis), and Rigidity (generalized muscle stiffness). Risk factors include initiation or dose change of neuroleptic medication, with depot injections carrying highest risk, and males being twice as likely to develop NMS. Treatment requires immediate discontinuation of the causative agent, supportive care with IV fluids, and management of complications including autonomic instability and rhabdomyolysis; mortality has decreased from 38% to under 10% with early recognition.